Tourmaline Bio, Inc. (TRML) Amount of Cash per Share

Risks for Tourmaline Bio, Inc. (TRML) are linked to clinical trial uncertainty and regulatory pressure, as evidenced by the cash per share for the period. The value 9.34 reflects the current financial stability metric. Tourmaline Bio, Inc. (TRML) focuses on therapies for orphan rheumatological pathologies, and its strategy relies on the development of the innovative monoclonal antibody TOUR006 for the treatment of atherosclerosis and the thyroid gland.
Comprehensive metric breakdowns and analytics for Tourmaline Bio Inc (TRML)

This indicator reflects the proportion of liquid assets per common share, allowing investors to decouple market volatility from the issuer's actual financial reserves. By analyzing the projected cash per share, an investor assesses the ability of Tourmaline Bio, Inc. (TRML) to fund the robotization of laboratory complexes and the automation of antibody screening without the urgent need to raise expensive external capital.